Author

Peter Irving

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN
MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN

Peter Irving  et al.

COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL
COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL

Peter Irving  et al.

NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE
NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE

Peter Irving  et al.

INTESTINAL ULTRASOUND INSTEAD OF ENDOSCOPY: LARGE POTENTIAL ROLE AND COST SAVINGS
INTESTINAL ULTRASOUND INSTEAD OF ENDOSCOPY: LARGE POTENTIAL ROLE AND COST SAVINGS

Peter Irving  et al.

UPDATE ON LABORATORY PARAMETERS RELATED TO MONITORING IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY
UPDATE ON LABORATORY PARAMETERS RELATED TO MONITORING IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY

Peter Irving  et al.

IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Peter Irving  et al.

PSYCHOLOGICAL MORBIDITY AMONG INFLAMMATORY BOWEL DISEASE PATIENTS DURING COVID-19: A UK COHORT STUDY
PSYCHOLOGICAL MORBIDITY AMONG INFLAMMATORY BOWEL DISEASE PATIENTS DURING COVID-19: A UK COHORT STUDY

Peter Irving  et al.

A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE
A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE

Peter Irving  et al.

GAMMA DELTA T CELL SELECTION BY BUTYROPHILIN-LIKE (BTNL) PROTEINS IS A CONSERVED TRAIT LIMITING IBD PROGRESSION
GAMMA DELTA T CELL SELECTION BY BUTYROPHILIN-LIKE (BTNL) PROTEINS IS A CONSERVED TRAIT LIMITING IBD PROGRESSION

Peter Irving  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Peter Irving  et al.

COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE
COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE

Peter Irving  et al.

THE EFFECTS OF COVID19 ON IBD PRESCRIBING AND SERVICE PROVISION
THE EFFECTS OF COVID19 ON IBD PRESCRIBING AND SERVICE PROVISION

Peter Irving  et al.

HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY
HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY

Peter Irving  et al.

HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ IN THE SEAVUE STUDY
HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ IN THE SEAVUE STUDY

Peter Irving  et al.

SURGICAL DOWNGRADING OF INFLAMMATORY BURDEN IN CROHN’S DISEASE OPTIMISES ANTI-TNF PHARMACOKINETICS
SURGICAL DOWNGRADING OF INFLAMMATORY BURDEN IN CROHN’S DISEASE OPTIMISES ANTI-TNF PHARMACOKINETICS

Peter Irving  et al.

Item 21 - 35 / 35
1
2